1. Market Research
  2. > All Companies
  3. > Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2015

Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2015

  • June 2015
  • -
  • Global Markets Direct
  • -
  • 569 pages

Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2015’, provides an overview of the Diffuse Large B-Cell Lymphoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diffuse Large B-Cell Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Diffuse Large B-Cell Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Diffuse Large B-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diffuse Large B-Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diffuse Large B-Cell Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diffuse Large B-Cell Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2015
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Diffuse Large B-Cell Lymphoma Overview 11
Therapeutics Development 12
Pipeline Products for Diffuse Large B-Cell Lymphoma - Overview 12
Pipeline Products for Diffuse Large B-Cell Lymphoma - Comparative Analysis 13
Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies 14
Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes 20
Diffuse Large B-Cell Lymphoma - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Diffuse Large B-Cell Lymphoma - Products under Development by Companies 24
Diffuse Large B-Cell Lymphoma - Products under Investigation by Universities/Institutes 32
Diffuse Large B-Cell Lymphoma - Companies Involved in Therapeutics Development 33
AbbVie Inc. 33
Affimed Therapeutics AG 34
Amgen Inc. 35
Aprogen, Inc. 36
Arrien Pharmaceuticals, LLC 37
Astellas Pharma Inc. 38
AstraZeneca Plc 39
Aurigene Discovery Technologies Limited 40
Bayer AG 41
BIND Therapeutics, Inc. 42
Biocon Limited 43
Boehringer Ingelheim GmbH 44
Bristol-Myers Squibb Company 45
Celgene Corporation 46
Cell>Point, L.L.C. 47
Cellular Biomedicine Group, Inc. 48
Constellation Pharmaceuticals, Inc. 49
CTI BioPharma Corp. 50
CureTech Ltd. 51
Curis, Inc. 52
Eisai Co., Ltd. 53
EpiZyme, Inc. 54
Erytech Pharma SA 55
F. Hoffmann-La Roche Ltd. 56
Genentech, Inc. 57
Gilead Sciences, Inc. 58
GlaxoSmithKline Plc 59
Idera Pharmaceuticals, Inc. 60
ImmunoGen, Inc. 61
Immunomedics, Inc. 62
Immunovaccine, Inc. 63
Incyte Corporation 64
Infinity Pharmaceuticals, Inc. 65
Johnson and Johnson 66
Karus Therapeutics Limited 67
Karyopharm Therapeutics, Inc. 68
Kite Pharma, Inc. 69
Mabion SA 70
MedImmune, LLC 71
Merck and Co., Inc. 72
Millennium Pharmaceuticals, Inc. 73
Mirati Therapeutics Inc. 74
Mirna Therapeutics, Inc. 75
Molplex Ltd. 76
MorphoSys AG 77
Nimbus Therapeutics, LLC 78
Nordic Nanovector AS 79
Novartis AG 80
Ono Pharmaceutical Co., Ltd. 81
Onyx Pharmaceuticals, Inc. 82
Pfizer Inc. 83
Pharmacyclics, Inc. 84
Philogen S.p.A. 85
Portola Pharmaceuticals, Inc. 86
Priaxon AG 87
ProNAi Therapeutics, Inc. 88
RedHill Biopharma Ltd. 89
Redx Pharma Ltd 90
Respiratorius AB 91
Rhizen Pharmaceuticals SA 92
Sandoz International GmbH 93
Seattle Genetics, Inc. 94
Taiho Pharmaceutical Co., Ltd. 95
TG Therapeutics, Inc. 96
Diffuse Large B-Cell Lymphoma - Therapeutics Assessment 97
Assessment by Monotherapy Products 97
Assessment by Combination Products 98
Assessment by Target 99
Assessment by Mechanism of Action 103
Assessment by Route of Administration 107
Assessment by Molecule Type 109
Drug Profiles 111
187Re-EC-G - Drug Profile 111
490-PXN - Drug Profile 112
ABC-294640 - Drug Profile 113
acalisib - Drug Profile 115
ACP-196 - Drug Profile 116
AFM-11 - Drug Profile 118
AFM-13 - Drug Profile 119
alisertib - Drug Profile 120
ARN-3236 - Drug Profile 124
ASN-002 - Drug Profile 125
asparaginase - Drug Profile 126
atezolizumab - Drug Profile 128
azacitidine - Drug Profile 131
AZD-2811 - Drug Profile 134
AZD-3965 - Drug Profile 135
AZD-9150 - Drug Profile 137
bendamustine hydrochloride - Drug Profile 138
Betalutin - Drug Profile 141
BI-836826 - Drug Profile 143
blinatumomab - Drug Profile 144
BLyS-gel - Drug Profile 147
BMS-986016 - Drug Profile 148
bortezomib - Drug Profile 149
brentuximab vedotin - Drug Profile 154
buparlisib hydrochloride - Drug Profile 160
BVX-20 - Drug Profile 164
carfilzomib - Drug Profile 165
CBM-C19.1 - Drug Profile 169
CBM-C20.1 - Drug Profile 170
CC-122 - Drug Profile 171
CC-223 - Drug Profile 173
Cell Therapy for Oncology - Drug Profile 174
Cell Therapy to Target CD19 for Oncology - Drug Profile 175
cerdulatinib - Drug Profile 176
coltuximab ravtansine - Drug Profile 177
copanlisib hydrochloride - Drug Profile 179
CPI-0610 - Drug Profile 183
CPI-169 - Drug Profile 184
CUDC-427 - Drug Profile 185
CUDC-907 - Drug Profile 186
daratumumab - Drug Profile 188
Darleukin - Drug Profile 191
denintuzumab mafodotin - Drug Profile 193
DPX-Survivac - Drug Profile 194
duvelisib - Drug Profile 197
E-6438 - Drug Profile 200
E-7449 - Drug Profile 202
epacadostat - Drug Profile 203
epratuzumab - Drug Profile 205
everolimus - Drug Profile 210
GS-5829 - Drug Profile 216
GS-9973 - Drug Profile 217
GSK-2816126 - Drug Profile 218
ibrutinib - Drug Profile 219
idelalisib - Drug Profile 225
IMGN-529 - Drug Profile 228
IMO-8400 - Drug Profile 230
inotuzumab ozogamicin - Drug Profile 232
IT-901 - Drug Profile 234
JNJ-64052781 - Drug Profile 235
KA-2237 - Drug Profile 236
KTE-C19 CAR - Drug Profile 237
lenalidomide - Drug Profile 239
MEDI-0680 - Drug Profile 243
MEDI-551 - Drug Profile 244
MK-2206 - Drug Profile 246
MK-8628 - Drug Profile 249
mocetinostat - Drug Profile 251
Monoclonal Antibody to Agonize CD40 for Diffuse Large B-Cell Lymphoma and Solid Tumors - Drug Profile 254
MOR-208 - Drug Profile 255
moxetumomab pasudotox - Drug Profile 257
MRX-34 - Drug Profile 259
NBD Peptide - Drug Profile 261
ND-2110 - Drug Profile 263
ND-2158 - Drug Profile 265
nivolumab - Drug Profile 267
obinutuzumab - Drug Profile 273
pecazine - Drug Profile 276
pembrolizumab - Drug Profile 277
pidilizumab - Drug Profile 284
pixantrone dimaleate - Drug Profile 286
PNT-2258 - Drug Profile 290
polatuzumab vedotin - Drug Profile 292
PRT-060318 - Drug Profile 294
Pt-EC-G - Drug Profile 295
rituximab biosimilar - Drug Profile 296
rituximab biosimilar - Drug Profile 297
rituximab biosimilar - Drug Profile 298
rituximab biosimilar - Drug Profile 300
rituximab biosimilar - Drug Profile 301
romidepsin - Drug Profile 302
RP-6530 - Drug Profile 305
ruxolitinib phosphate - Drug Profile 306
selinexor - Drug Profile 311
SGN-CD70A - Drug Profile 316
SH-7129 - Drug Profile 317
Small Molecule to Inhibit BTK for Cancer and Autoimmune disorders - Drug Profile 319
Small Molecule to Inhibit IRAK-4 Cancer and Inflammation - Drug Profile 320
Small Molecules for Diffuse Large B Cell Lymphoma - Drug Profile 321
Small Molecules to Inhibit IRAK4 for Immunology and Oncology - Drug Profile 322
Small Molecules to Inhibit NF-kappa B for Diffuse Large B-Cell Lymphoma - Drug Profile 323
sotrastaurin acetate - Drug Profile 324
spebrutinib besylate - Drug Profile 326
Synthetic Peptide to Inhibit Bcl-6 for Diffuse Large B-Cell Lymphoma and Acute Lymphoblastic Leukemia - Drug Profile 328
TAK-659 - Drug Profile 329
TAS-5567 - Drug Profile 330
tisagenlecleucel-T - Drug Profile 331
ublituximab [INN] + TGR-1202 - Drug Profile 333
ulocuplumab - Drug Profile 334
urelumab - Drug Profile 336
valproate sodium - Drug Profile 338
venetoclax - Drug Profile 339
vorinostat - Drug Profile 342
Diffuse Large B-Cell Lymphoma - Recent Pipeline Updates 346
Diffuse Large B-Cell Lymphoma - Dormant Projects 549
Diffuse Large B-Cell Lymphoma - Discontinued Products 551
Diffuse Large B-Cell Lymphoma - Product Development Milestones 553
Featured News and Press Releases 553
Appendix 560
Methodology 560
Coverage 560
Secondary Research 560
Primary Research 560
Expert Panel Validation 560
Contact Us 560
Disclaimer 561

List of Tables
Number of Products under Development for Diffuse Large B-Cell Lymphoma, H1 2015 20
Number of Products under Development for Diffuse Large B-Cell Lymphoma - Comparative Analysis, H1 2015 21
Number of Products under Development by Companies, H1 2015 23
Number of Products under Development by Companies, H1 2015 (Contd..1) 24
Number of Products under Development by Companies, H1 2015 (Contd..2) 25
Number of Products under Development by Companies, H1 2015 (Contd..3) 26
Number of Products under Development by Companies, H1 2015 (Contd..4) 27
Number of Products under Investigation by Universities/Institutes, H1 2015 28
Comparative Analysis by Late Stage Development, H1 2015 29
Comparative Analysis by Clinical Stage Development, H1 2015 30
Comparative Analysis by Early Stage Development, H1 2015 31
Products under Development by Companies, H1 2015 32
Products under Development by Companies, H1 2015 (Contd..1) 33
Products under Development by Companies, H1 2015 (Contd..2) 34
Products under Development by Companies, H1 2015 (Contd..3) 35
Products under Development by Companies, H1 2015 (Contd..4) 36
Products under Development by Companies, H1 2015 (Contd..5) 37
Products under Development by Companies, H1 2015 (Contd..6) 38
Products under Development by Companies, H1 2015 (Contd..7) 39
Products under Investigation by Universities/Institutes, H1 2015 40
Diffuse Large B-Cell Lymphoma - Pipeline by AbbVie Inc., H1 2015 41
Diffuse Large B-Cell Lymphoma - Pipeline by Affimed Therapeutics AG, H1 2015 42
Diffuse Large B-Cell Lymphoma - Pipeline by Amgen Inc., H1 2015 43
Diffuse Large B-Cell Lymphoma - Pipeline by Aprogen, Inc., H1 2015 44
Diffuse Large B-Cell Lymphoma - Pipeline by Arrien Pharmaceuticals, LLC, H1 2015 45
Diffuse Large B-Cell Lymphoma - Pipeline by Astellas Pharma Inc., H1 2015 46
Diffuse Large B-Cell Lymphoma - Pipeline by AstraZeneca Plc, H1 2015 47
Diffuse Large B-Cell Lymphoma - Pipeline by Aurigene Discovery Technologies Limited, H1 2015 48
Diffuse Large B-Cell Lymphoma - Pipeline by Bayer AG, H1 2015 49
Diffuse Large B-Cell Lymphoma - Pipeline by BIND Therapeutics, Inc., H1 2015 50
Diffuse Large B-Cell Lymphoma - Pipeline by Biocon Limited, H1 2015 51
Diffuse Large B-Cell Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2015 52
Diffuse Large B-Cell Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2015 53
Diffuse Large B-Cell Lymphoma - Pipeline by Celgene Corporation, H1 2015 54
Diffuse Large B-Cell Lymphoma - Pipeline by Cell>Point, L.L.C., H1 2015 55
Diffuse Large B-Cell Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H1 2015 56
Diffuse Large B-Cell Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H1 2015 57
Diffuse Large B-Cell Lymphoma - Pipeline by CTI BioPharma Corp., H1 2015 58
Diffuse Large B-Cell Lymphoma - Pipeline by CureTech Ltd., H1 2015 59
Diffuse Large B-Cell Lymphoma - Pipeline by Curis, Inc., H1 2015 60
Diffuse Large B-Cell Lymphoma - Pipeline by Eisai Co., Ltd., H1 2015 61
Diffuse Large B-Cell Lymphoma - Pipeline by EpiZyme, Inc., H1 2015 62
Diffuse Large B-Cell Lymphoma - Pipeline by Erytech Pharma SA, H1 2015 63
Diffuse Large B-Cell Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 64
Diffuse Large B-Cell Lymphoma - Pipeline by Genentech, Inc., H1 2015 65
Diffuse Large B-Cell Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2015 66
Diffuse Large B-Cell Lymphoma - Pipeline by GlaxoSmithKline Plc, H1 2015 67
Diffuse Large B-Cell Lymphoma - Pipeline by Idera Pharmaceuticals, Inc., H1 2015 68
Diffuse Large B-Cell Lymphoma - Pipeline by ImmunoGen, Inc., H1 2015 69
Diffuse Large B-Cell Lymphoma - Pipeline by Immunomedics, Inc., H1 2015 70
Diffuse Large B-Cell Lymphoma - Pipeline by Immunovaccine, Inc., H1 2015 71
Diffuse Large B-Cell Lymphoma - Pipeline by Incyte Corporation, H1 2015 72
Diffuse Large B-Cell Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2015 73
Diffuse Large B-Cell Lymphoma - Pipeline by Johnson and Johnson, H1 2015 74
Diffuse Large B-Cell Lymphoma - Pipeline by Karus Therapeutics Limited, H1 2015 75
Diffuse Large B-Cell Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 76
Diffuse Large B-Cell Lymphoma - Pipeline by Kite Pharma, Inc., H1 2015 77
Diffuse Large B-Cell Lymphoma - Pipeline by Mabion SA, H1 2015 78
Diffuse Large B-Cell Lymphoma - Pipeline by MedImmune, LLC, H1 2015 79
Diffuse Large B-Cell Lymphoma - Pipeline by Merck and Co., Inc., H1 2015 80
Diffuse Large B-Cell Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 81
Diffuse Large B-Cell Lymphoma - Pipeline by Mirati Therapeutics Inc., H1 2015 82
Diffuse Large B-Cell Lymphoma - Pipeline by Mirna Therapeutics, Inc., H1 2015 83
Diffuse Large B-Cell Lymphoma - Pipeline by Molplex Ltd., H1 2015 84
Diffuse Large B-Cell Lymphoma - Pipeline by MorphoSys AG, H1 2015 85
Diffuse Large B-Cell Lymphoma - Pipeline by Nimbus Therapeutics, LLC, H1 2015 86
Diffuse Large B-Cell Lymphoma - Pipeline by Nordic Nanovector AS, H1 2015 87
Diffuse Large B-Cell Lymphoma - Pipeline by Novartis AG, H1 2015 88
Diffuse Large B-Cell Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 89
Diffuse Large B-Cell Lymphoma - Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 90
Diffuse Large B-Cell Lymphoma - Pipeline by Pfizer Inc., H1 2015 91
Diffuse Large B-Cell Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2015 92
Diffuse Large B-Cell Lymphoma - Pipeline by Philogen S.p.A., H1 2015 93
Diffuse Large B-Cell Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H1 2015 94
Diffuse Large B-Cell Lymphoma - Pipeline by Priaxon AG, H1 2015 95
Diffuse Large B-Cell Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H1 2015 96
Diffuse Large B-Cell Lymphoma - Pipeline by RedHill Biopharma Ltd., H1 2015 97
Diffuse Large B-Cell Lymphoma - Pipeline by Redx Pharma Ltd, H1 2015 98
Diffuse Large B-Cell Lymphoma - Pipeline by Respiratorius AB, H1 2015 99
Diffuse Large B-Cell Lymphoma - Pipeline by Rhizen Pharmaceuticals SA, H1 2015 100
Diffuse Large B-Cell Lymphoma - Pipeline by Sandoz International GmbH, H1 2015 101
Diffuse Large B-Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2015 102
Diffuse Large B-Cell Lymphoma - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2015 103
Diffuse Large B-Cell Lymphoma - Pipeline by TG Therapeutics, Inc., H1 2015 104
Assessment by Monotherapy Products, H1 2015 105
Assessment by Combination Products, H1 2015 106
Number of Products by Stage and Target, H1 2015 108
Number of Products by Stage and Mechanism of Action, H1 2015 112
Number of Products by Stage and Route of Administration, H1 2015 116
Number of Products by Stage and Molecule Type, H1 2015 118
Diffuse Large B-Cell Lymphoma Therapeutics - Recent Pipeline Updates, H1 2015 354
Diffuse Large B-Cell Lymphoma - Dormant Projects, H1 2015 557
Diffuse Large B-Cell Lymphoma - Dormant Projects (Contd..1), H1 2015 558
Diffuse Large B-Cell Lymphoma - Discontinued Products, H1 2015 559
Diffuse Large B-Cell Lymphoma - Discontinued Products (Contd..1), H1 2015 560

List of Figures
Number of Products under Development for Diffuse Large B-Cell Lymphoma, H1 2015 20
Number of Products under Development for Diffuse Large B-Cell Lymphoma - Comparative Analysis, H1 2015 21
Number of Products under Development by Companies, H1 2015 22
Number of Products under Investigation by Universities/Institutes, H1 2015 28
Comparative Analysis by Clinical Stage Development, H1 2015 30
Comparative Analysis by Early Stage Products, H1 2015 31
Assessment by Monotherapy Products, H1 2015 105
Number of Products by Top 10 Targets, H1 2015 107
Number of Products by Stage and Top 10 Targets, H1 2015 107
Number of Products by Top 10 Mechanism of Actions, H1 2015 111
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 111
Number of Products by Top 10 Routes of Administration, H1 2015 115
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 115
Number of Products by Top 10 Molecule Types, H1 2015 117
Number of Products by Stage and Top 10 Molecule Types, H1 2015 117

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Pancreatic Endocrine Tumor - Pipeline Review, H1 2015

Pancreatic Endocrine Tumor - Pipeline Review, H1 2015

  • $ 2 000
  • Company report
  • April 2015
  • by Global Markets Direct

Pancreatic Endocrine Tumor - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Pancreatic Endocrine Tumor - Pipeline Review, H1 2015’, provides an overview of the Pancreatic Endocrine Tumor’s ...

Ureter Cancer - Pipeline Review, H1 2015

Ureter Cancer - Pipeline Review, H1 2015

  • $ 2 000
  • Company report
  • April 2015
  • by Global Markets Direct

Ureter Cancer - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Ureter Cancer - Pipeline Review, H1 2015’, provides an overview of the Ureter Cancer’s therapeutic pipeline. This report ...

Pheochromocytoma - Pipeline Review, H1 2015

Pheochromocytoma - Pipeline Review, H1 2015

  • $ 2 000
  • Company report
  • April 2015
  • by Global Markets Direct

Pheochromocytoma - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Pheochromocytoma - Pipeline Review, H1 2015’, provides an overview of the Pheochromocytoma’s therapeutic pipeline. ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.